WO2012172337A3 - Treating cardiovascular disease - Google Patents

Treating cardiovascular disease Download PDF

Info

Publication number
WO2012172337A3
WO2012172337A3 PCT/GB2012/051346 GB2012051346W WO2012172337A3 WO 2012172337 A3 WO2012172337 A3 WO 2012172337A3 GB 2012051346 W GB2012051346 W GB 2012051346W WO 2012172337 A3 WO2012172337 A3 WO 2012172337A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
cardiovascular disease
treating cardiovascular
ccr1
patient
Prior art date
Application number
PCT/GB2012/051346
Other languages
French (fr)
Other versions
WO2012172337A2 (en
Inventor
Graham Cotton
Ola Winqvist
Original Assignee
Ith Immune Therapy Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ith Immune Therapy Holdings filed Critical Ith Immune Therapy Holdings
Publication of WO2012172337A2 publication Critical patent/WO2012172337A2/en
Publication of WO2012172337A3 publication Critical patent/WO2012172337A3/en
Priority to US14/105,628 priority Critical patent/US9726666B2/en
Priority to US15/629,705 priority patent/US10429385B2/en
Priority to US15/629,713 priority patent/US10408832B2/en
Priority to US15/629,691 priority patent/US10451620B2/en
Priority to US15/629,708 priority patent/US10401357B2/en
Priority to US15/629,697 priority patent/US10502736B2/en
Priority to US15/629,700 priority patent/US10422800B2/en
Priority to US16/537,224 priority patent/US20190361020A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating cardiovascular disease comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR1 and/or CCR7 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally CCR2, CCR1 and/or CCR7 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.
PCT/GB2012/051346 2011-06-13 2012-06-13 Treating cardiovascular disease WO2012172337A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/105,628 US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases
US15/629,705 US10429385B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with sepsis
US15/629,713 US10408832B2 (en) 2011-06-13 2017-06-21 Treating mental disorders
US15/629,691 US10451620B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with metabolic syndrome
US15/629,708 US10401357B2 (en) 2011-06-13 2017-06-21 Treating cancer
US15/629,697 US10502736B2 (en) 2011-06-13 2017-06-21 Treating multiple sclerosis
US15/629,700 US10422800B2 (en) 2011-06-13 2017-06-21 Treating respiratory conditions
US16/537,224 US20190361020A1 (en) 2011-06-13 2019-08-09 Treating respiratory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496184P 2011-06-13 2011-06-13
US61/496,184 2011-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051353 Continuation-In-Part WO2012172343A2 (en) 2011-06-13 2012-06-13 Treating primary sclerosing cholangitis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2012/051352 Continuation-In-Part WO2012172342A2 (en) 2011-06-13 2012-06-13 Treating multiple sclerosis
US14/105,628 Continuation-In-Part US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases

Publications (2)

Publication Number Publication Date
WO2012172337A2 WO2012172337A2 (en) 2012-12-20
WO2012172337A3 true WO2012172337A3 (en) 2013-03-07

Family

ID=46317433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051346 WO2012172337A2 (en) 2011-06-13 2012-06-13 Treating cardiovascular disease

Country Status (1)

Country Link
WO (1) WO2012172337A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2024094685A1 (en) * 2022-10-31 2024-05-10 Orion Biotechnology Holding Sa Ccr2 inhibitors and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (en) * 2004-07-30 2006-06-01 Adexter Gmbh Filtration process and assembly for removing harmful substances from human blood e.g. human immunodeficiency virus, Herpes virus, or plasmodia, comprises a reactor vessel of a biocompatible material
WO2007133147A1 (en) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Method and means for treating inflammatory bowel disease
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (en) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Biotinylated chemokine antibody conjugate
AU2009283199B2 (en) 2008-08-18 2015-08-13 Amgen Fremont Inc. Antibodies to CCR2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE102005036505A1 (en) * 2004-07-30 2006-06-01 Adexter Gmbh Filtration process and assembly for removing harmful substances from human blood e.g. human immunodeficiency virus, Herpes virus, or plasmodia, comprises a reactor vessel of a biocompatible material
WO2007133147A1 (en) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Method and means for treating inflammatory bowel disease
WO2010029317A2 (en) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHARO ISRAEL F ET AL: "Chemokines in the pathogenesis of vascular disease.", CIRCULATION RESEARCH 29 OCT 2004 LNKD- PUBMED:15514167, vol. 95, no. 9, 29 October 2004 (2004-10-29), pages 858 - 866, XP055036997, ISSN: 1524-4571 *
M. N. SARAFI ET AL: "Murine Monocyte Chemoattractant Protein (MCP)-5: A Novel CC Chemokine That Is a Structural and Functional Homologue of Human MCP-1", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 1, 1 January 1997 (1997-01-01), pages 99 - 110, XP055035882, ISSN: 0022-1007, DOI: 10.1084/jem.185.1.99 *
NIU JIANLI ET AL: "Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications.", CLINICAL SCIENCE (LONDON, ENGLAND : 1979) AUG 2009 LNKD- PUBMED:19566488, vol. 117, no. 3, August 2009 (2009-08-01), pages 95 - 109, XP002682220, ISSN: 1470-8736 *
THERESA J REAPE ET AL: "Chemokines and atherosclerosis", ATHEROSCLEROSIS, vol. 147, no. 2, 1 December 1999 (1999-12-01), pages 213 - 225, XP055035889, ISSN: 0021-9150, DOI: 10.1016/S0021-9150(99)00346-9 *

Also Published As

Publication number Publication date
WO2012172337A2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012172341A3 (en) Treating cancer
WO2010029317A3 (en) Treating inflammatory conditions
WO2010135603A3 (en) Method for cancer detection, diagnosis and prognosis
WO2011008520A3 (en) Analyte testing methods and device for calculating basal insulin therapy
WO2014011536A3 (en) Biologic sample collection devices and methods of production and use thereof
WO2010008739A3 (en) Aryl gpr119 agonists and uses thereof
EP2244663A4 (en) Blood clot removal device, system, and method
WO2012047629A3 (en) Selective removal of age-modified cells for treatment of ather0sclerosis
WO2012061835A3 (en) Apparatus and method for non-invasively detecting diseases that affect structural properties in biological tissues
IL222252A (en) System, assembly and method for the detection and diagnosis of biological rhythm disorders
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2010091049A3 (en) Diagnosis and treatment of cancer
EA201101568A1 (en) TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2014093051A3 (en) Cardiac stem cells and methods of identifying and using the same
PL398781A1 (en) Methods and kits for predicting the risk of reaction to infusion and lack of antibody-mediated responses by monitoring serum uric acid during therapy with pegylated uricase
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2010002895A3 (en) Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
WO2012064834A3 (en) Methods for organ regeneration
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
MX2008015392A (en) Treatment of ischemic disease using erythropoietin.
WO2012172337A3 (en) Treating cardiovascular disease
WO2008157222A3 (en) Device and methods for introducing a catheter
WO2012172343A3 (en) Treating primary sclerosing cholangitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727912

Country of ref document: EP

Kind code of ref document: A2